Altheos raises $20M, in-licenses glaucoma compound

Altheos Inc. (South San Francisco, Calif.) raised $20 million in a series A round on Monday and announced a deal with Asahi Kasei Pharma Corp. Asahi granted Altheos exclusive, worldwide rights, excluding Japan and Korea, to develop and commercialize ATS907 and related molecules. The topical Rho kinase inhibitor is in late-stage preclinical testing to treat glaucoma. The license also includes Asahi's library of AK138 small molecule Rho kinase inhibitors for glaucoma and other ophthalmic indications. Financial terms were not disclosed. ...